HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,646,413 | +5.2% | 95,460 | -0.6% | 0.02% | +15.4% |
| Q2 2023 | $3,464,842 | -5.4% | 96,056 | +0.2% | 0.01% | -7.1% |
| Q1 2023 | $3,663,288 | -53.4% | 95,910 | -30.5% | 0.01% | -12.5% |
| Q4 2022 | $7,855,454 | +96.1% | 138,014 | +36.3% | 0.02% | -11.1% |
| Q3 2022 | $4,005,000 | -11.0% | 101,277 | -1.0% | 0.02% | -14.3% |
| Q2 2022 | $4,502,000 | +120.7% | 102,326 | +100.0% | 0.02% | +133.3% |
| Q1 2022 | $2,040,000 | -0.8% | 51,163 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $2,057,000 | +10.3% | 51,163 | +11.6% | 0.01% | +12.5% |
| Q3 2021 | $1,865,000 | -10.8% | 45,851 | -0.4% | 0.01% | -11.1% |
| Q2 2021 | $2,090,000 | +4.4% | 46,018 | -4.2% | 0.01% | 0.0% |
| Q1 2021 | $2,002,000 | -12.3% | 48,018 | -10.2% | 0.01% | -10.0% |
| Q4 2020 | $2,283,000 | +49.3% | 53,465 | -8.1% | 0.01% | +25.0% |
| Q3 2020 | $1,529,000 | +13.4% | 58,166 | +15.7% | 0.01% | +14.3% |
| Q2 2020 | $1,348,000 | +41.0% | 50,282 | -5.4% | 0.01% | +16.7% |
| Q1 2020 | $956,000 | +12.2% | 53,148 | +10.7% | 0.01% | +50.0% |
| Q4 2019 | $852,000 | +25.5% | 48,018 | +9.8% | 0.00% | +33.3% |
| Q3 2019 | $679,000 | -9.5% | 43,741 | +0.2% | 0.00% | -25.0% |
| Q2 2019 | $750,000 | +4.3% | 43,643 | -2.2% | 0.00% | 0.0% |
| Q1 2019 | $719,000 | +1.1% | 44,643 | -8.2% | 0.00% | 0.0% |
| Q4 2018 | $711,000 | +13.9% | 48,643 | +41.6% | 0.00% | +33.3% |
| Q3 2018 | $624,000 | +7.6% | 34,362 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $580,000 | -13.8% | 34,362 | 0.0% | 0.00% | -25.0% |
| Q1 2018 | $673,000 | -3.3% | 34,362 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $696,000 | +16.6% | 34,362 | 0.0% | 0.00% | +33.3% |
| Q3 2017 | $597,000 | +35.4% | 34,362 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $441,000 | +6.5% | 34,362 | +7.5% | 0.00% | +50.0% |
| Q1 2017 | $414,000 | +31.0% | 31,957 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $316,000 | -19.4% | 31,957 | -1.5% | 0.00% | 0.0% |
| Q3 2016 | $392,000 | +23.7% | 32,439 | -11.7% | 0.00% | 0.0% |
| Q2 2016 | $317,000 | +4.3% | 36,738 | +14.5% | 0.00% | 0.0% |
| Q1 2016 | $304,000 | -12.6% | 32,081 | +108.1% | 0.00% | 0.0% |
| Q2 2015 | $348,000 | +46.8% | 15,417 | -7.1% | 0.00% | +100.0% |
| Q1 2015 | $237,000 | +74.3% | 16,597 | +11.9% | 0.00% | 0.0% |
| Q3 2014 | $136,000 | – | 14,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |